Double trouble for TB

During the period of the granted NADP Value Proposition Voucher as well as the Lead Development Voucher, Bernard van Vliet (Integrex) and Nicole van der Wel (Amsterdam UMC-AMC) have collaborated on the development plan for the application of a novel drug strategy to combat Mycobacterium tuberculosis. As the compound we have preliminary data on, is an already FDA approved and clinically applied compound, ample information is available about the safety and cytotoxicity, manufacturing outline, business perspectives and we could produce a regulatory strategy. The first steps towards preparing this project to animal studies and clinical trials have now been taken, thanks to the funding of the NADP.

Dr. Nicole van der Wel, Amsterdam UMC